Glial fibrillary acidic protein (GFAP) in plasma is a proxy for astrocytic activity and is elevated in amyloid-β (Aβ)-positive individuals, making GFAP a potential blood-based biomarker for Alzheimer’s disease (AD).
We assessed plasma GFAP in 72 Aβ-positive participants diagnosed with the visual or language variant of AD who underwent Aβ- and tau-PET. Fifty-nine participants had follow-up imaging. Linear regression was applied on GFAP and imaging quantities.
GFAP did not correlate with Aβ- or tau-PET cross-sectionally. There was a limited positive correlation between GFAP and rates of tau accumulation, particularly in the language variant of AD, although associations were weaker after removing one outlier patient with the highest GFAP level.
Among Aβ-positive AD participants with atypical presentations, plasma GFAP did not correlate with levels of AD pathology on PET, suggesting that the associations between GFAP and AD pathology might plateau during the advanced phase of the disease.

If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.

This post is Copyright: Irene Sintini,
Neha Atulkumar Singh,
Danni Li,
Michelle M. Mielke,
Mary M. Machulda,
Christopher G. Schwarz,
Matthew L. Senjem,
Clifford R. Jack Jr.,
Val J. Lowe,
Jonathan Graff‐Radford,
Keith A. Josephs,
Jennifer L. Whitwell | March 26, 2024

Wiley: Alzheimer’s & Dementia: Table of Contents